Response to hepatitis B vaccination in high risk population.
Artigo
em Inglês
| IMSEAR
| ID: sea-112246
ABSTRACT
Hepatitis B vaccine is well established as very efficacious, but immune response to the vaccine is highly individual specific. A study involving fifty vaccinees was undertaken at the Hepatitis Laboratory, National Institute of Communicable Disease, Delhi. One ml (20 microgram) of Engerix B vaccine (recombinant yeast derived vaccine) was administered in the standard three dose schedule (0, 1 and 6 months). The sero-conversion of the vaccinees was 24%, 66%, 76% and 78% at 1 month, 6 months, 7 months, and 12 months respectively. There was no seroconversion in 22% of the vaccinees. Sero-conversion was assessed using Macro ELISA test (Ausab, Abbott Labs) for Anti HBs reactivity.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Fatores de Tempo
/
Feminino
/
Humanos
/
Masculino
/
Ensaio de Imunoadsorção Enzimática
/
Vacinas Sintéticas
/
Biomarcadores
/
Estudos Prospectivos
/
Esquemas de Imunização
/
Vacinação
Tipo de estudo:
Estudo de etiologia
/
Estudo observacional
/
Fatores de risco
Idioma:
Inglês
Ano de publicação:
2000
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS